

Sanofi Pasteur Congratulates and Supports the CPHA in Shaping the Future of Public Health in Canada

TORONTO, June 10 /CNW Telbec/ - As a longstanding partner in Canada's public health system, sanofi pasteur congratulates the Canadian Public Health Association (CPHA) for their 100 years of leadership and service to our country's public health.

"We share a tradition of protecting and safeguarding public health with the CPHA that spans close to a century," said Mark Lievonon, President, Sanofi Pasteur Limited. "CPHA was there when we created Connaught Laboratories in 1917 in Toronto and both the CPHA and sanofi pasteur shared a strong commitment to the eradication of smallpox and the control of other infectious diseases like diphtheria, tetanus, polio and whooping cough. Now as the North American vaccine centre of excellence for biopharmaceutical development as well as a global manufacturing centre of excellence, we continue to innovate for the health of Canadians and collaborate with the CPHA to help shape the future of public health."

Great public health achievements

Sanofi Pasteur is proud to be the CPHA Centenary Presenting Partner at the conference to mark their great public health achievements. Among the public health achievements championed by the CPHA which we join them in celebrating are:

- Vaccination - In the last 50 years, immunization has saved more lives in Canada than any other health intervention.
- Motor-vehicle safety - many lives have been saved and injuries prevented thanks to a decrease in alcohol-related collisions and increased seatbelt use.
- Control of infectious disease has been a fundamental goal since the beginning of public health in Canada.

There are twelve great public health achievements being celebrated in this CPHA centennial. To learn more, visit the great achievements web site at <http://cpha100.ca/12-great-achievements/> and celebrate them all.

Sanofi pasteur milestones

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, is a company built on nearly a century of science. Our roots have grown out of Dr. John FitzGerald's pioneering vision and his collaboration with the University of Toronto. Among the Canadian milestones that we have celebrated are the following:

- Creation of Connaught Antitoxin Laboratories and University Farm in 1917 in Toronto, where sanofi pasteur is still located today.
- In the early 1920s, worked with doctors Banting and Best to begin commercializing insulin; the site of the world's first large scale insulin production.
- During the Second World War, Connaught Laboratories helped commercialize penicillin.
- In 1954, Connaught supplied all polio virus fluids used in the mass American field trial of the Salk Polio vaccine, which went on to end the Polio epidemic in North America.
- Developed a freeze-dried smallpox vaccine in the 1960s, which played a major role in the global eradication of smallpox.
- The 1990s brought the development and manufacture of a new generation pertussis (or whooping cough vaccine) which consists of five specific components of the pertussis antigen. This was combined with diphtheria, tetanus, polio and Haemophilus influenzae type b (a form of bacterial meningitis) and helps ward off these diseases in more than 50 countries worldwide.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is

the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

For further information: Nancy Simpson, Director, Communications, Sanofi Pasteur Limited, 416-667-2955, nancy.simpson@sanofipasteur.com; Stacey O'Rourke, NATIONAL Public Relations, (416) 848-1426 x 226, sorourke@national.ca
